Abstract
Objective: To determine the beneficial antipsychotic effects of aspirin plus atypical antipsychotic agents in the
treatment of schizophrenia.
Study Design:A double blind placebo controlled study.
Place and Duration of Study: The study was conducted in Psychiatry ward of Imam Reza and Shahid Hashemi
Mental Hospital in Arak, from April to December 2011.
Materials and Methods: This double blind placebo controlled study was conducted on 60 patients with
schizophrenia. Patients were assigned to case group who received an atypical antipsychotic agent (olanzapine,
risperidone, clozapine) as the standard treatment of the schizophrenia plus aspirin 1000 mg /daily (aspirin or
case group n=30), and 30 patients received standard treatment and placebo (control group, n=30). The PANSS
questionnaire was used to evaluate patients at 0, 2,4,6 and 8 weeks after treatment. SPSS software was used for
data analysis. Student's t-test was applied and repeated measurement test to compare two groups
Results: The difference between two groups regarding positive and negative symptoms was not significant
(Repeated Measure/P=0.20 and P =0.20 respectively). However, there was a significant difference between two
groups regarding general and total symptoms (Repeated Measure/P=0.003 and P=0.032 respectively). The
results did not show any remarkable related side effects to aspirin in two groups.
Conclusion: The trial revealed that aspirin 1000 mg /day in combination with antipsychotic drugs for 8 weeks is
an effective agent for the reduction of general and total symptoms of schizophrenia. Nonetheless, it did not
modify the positive and negative symptoms.
Hamidreza Jamilian, Gevick Hacoupian. (2017) The Effect of Aspirin on Schizophrenia; A Double Blind Placebo Controlled Study, Journal of Islamic International Medical College, Volume-12, Issue-4.
-
Views
1009 -
Downloads
85
Article Details
Volume
Issue
Type
Language
Received At
Accepted At
